Welcome back to another episode of MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women’s health. In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of…
Continue Reading
Converge Bio has raised $5.5 million in seed funding led by TLV Partners.WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs…
What You Should Know:
– Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners.
– Converge Bio’s platform uses large language…
Continue Reading
Former President Donald Trump’s return to the White House is certain to bring about changes across many facets of the healthcare sector — including reproductive care, federal insurance programs and prescription drugs.
Experts interviewed for…
Continue Reading
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD) dubbed HG202, developed…
Continue Reading
In a series of articles to promote INVEST 2025 in Chicago April 29-30, we are highlighting investment insights and perspectives. At the centerpiece of this boutique event for traditional and strategic healthcare investors, startups…
Continue Reading
The past few years have seen a surge in demand for healthcare AI. This doesn’t show any signs of stopping soon — with three-quarters of the country’s providers and payers reporting that they have…
Continue Reading
Sam Anwar, Chief Technology Officer, eClinical Solutions
McKinsey & Company estimates it takes up to 12 years to introduce a new drug to the market – a lengthy timeline comprised of many factors including technology…
Continue Reading
AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.According to Owkin, BRCA…
Continue Reading
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in…
